Article Correctness Is Author's Responsibility: FDA Approval of Tisagenlecleucel as CAR-T Therapy for Leukemia

This Viewpoint uses FDA approval of tisagenlecleucel, the first chimeric antigen receptor T-cell (CAR-T) agent approved for human use, to discuss escalating drug prices for oncology therapies and the complex considerations of outcomes and value that should justify the pricing.
Posted in Uncategorized